Company news

Denali Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV: IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

February 11, 2021

Denali Therapeutics to Present New Data on ETV: IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

February 4, 2021

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

January 10, 2021

Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

January 7, 2021

Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV: IDS (DNL310) in Hunter Syndrome (MPS II)

November 9, 2020

Denali Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

November 4, 2020

Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today

October 14, 2020

Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen

October 6, 2020

Denali Therapeutics to Host Webinar on Transporting Biotherapeutics Across the Blood-Brain Barrier

September 29, 2020

Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

August 6, 2020

Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients

August 5, 2020

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

August 5, 2020

Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients

July 28, 2020

Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi

June 8, 2020

Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine

May 26, 2020

Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update

May 6, 2020

Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic

April 1, 2020

Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

February 26, 2020

Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 30, 2020

Denali Therapeutics Announces Pricing of Public Offering of Common Stock

January 27, 2020

Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease

January 13, 2020

Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights

November 5, 2019

← Newer news releases

Calls

Decks